Secukinumab (AIN-457) for the treatment of Psoriasis

被引：10

作者：

Jaleel, Tarannum ^{[1
]}

Elmets, Craig ^{[1
]}

Weinkle, Allison ^{[3
]}

Kassira, Sama ^{[2
]}

Elewski, Boni ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Dept Dermatol, EFH 414,1530 3rd Ave S, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA

[3] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2016年 / 9卷 / 02期

关键词：

pharmacology; IL-17; Th; 17; AIN-457; psoriasis; secukinumab; SEVERE PLAQUE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; OPEN-LABEL; MULTIPLE-SCLEROSIS; TH17; CELLS; INFLIXIMAB INDUCTION;

D O I：

10.1586/17512433.2016.1129894

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review will address the rationale for targeting the IL-23/Th17/IL-17 axis, the role of IL-17 and Th17 cells in psoriasis and other chronic inflammatory diseases, and will examine pre-clinical studies, pharmacologic properties, clinical efficacy, and the safety profile of secukinumab.

引用

页码：187 / 202

页数：16

共 50 条

[41] Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
Qingqing Yang
Jiajie Lyu
Yu Gui
Shuling Yu
Jiajie Chen
Haoxue Zhang
Shengxiu Liu
Allergy, Asthma & Clinical Immunology, 19
[42] Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
Morita, Akimichi
Tani, Yumiko
Matsumoto, Kazuko
Yamaguchi, Masako
Teshima, Rie
Ohtsuki, Mamitaro
JOURNAL OF DERMATOLOGY, 2020, 47 (05) : 452 - 457
[43] Progression of Pre-Existing Vitiligo during Secukinumab Treatment for Psoriasis
Kim, Jin Cheol
Lee, Eun-So
ANNALS OF DERMATOLOGY, 2023, 35 : S117 - S121
[44] Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report
Yang, Qingqing
Lyu, Jiajie
Gui, Yu
Yu, Shuling
Chen, Jiajie
Zhang, Haoxue
Liu, Shengxiu
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2023, 19 (01)
[45] Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
Jashin J. Wu
Joseph F. Merola
Steven R. Feldman
Alan Menter
Mark Lebwohl
Dermatology and Therapy, 2020, 10 : 351 - 364
[46] Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
Wu, Jashin J.
Merola, Joseph F.
Feldman, Steven R.
Menter, Alan
Lebwohl, Mark
DERMATOLOGY AND THERAPY, 2020, 10 (03) : 351 - 364
[47] The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity
Wu, Lan-Tu-Ya
Qiao, Zhu-Hui
Tian, Jia-Bin
Lin, Jia-Lin
Hou, Su-Chun
Liu, Xiao-Ming
SKIN RESEARCH AND TECHNOLOGY, 2023, 29 (07)
[48] Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
Godse, Kiran
INDIAN JOURNAL OF DERMATOLOGY, 2017, 62 (02) : 195 - 199
[49] Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre
Laoise Griffin
Jennifer Boggs
Bart Ramsay
Caitriona Hackett
Kashif Ahmad
Maeve Lynch
Irish Journal of Medical Science (1971 -), 2021, 190 : 639 - 641
[50] Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre
Griffin, Laoise
Boggs, Jennifer
Ramsay, Bart
Hackett, Caitriona
Ahmad, Kashif
Lynch, Maeve
IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (02) : 639 - 641

← 1 2 3 4 5 →